iBio (IBIO) Other Non-Current Liabilities (2022 - 2023)

iBio's (IBIO) quarterly Other Non-Current Liabilities came in at $263000.0 in Q3 2023, down 50.09% on a QoQ basis from $527000.0 in Q2 2023.

iBio (IBIO) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends

iBio (IBIO) has 2 years of Other Non-Current Liabilities data on file, last reported at $263000.0 in Q3 2023.

On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $263000.0 in Q3 2023; TTM through Sep 2023 was $263000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $527000.0, changed N/A from the prior year.
Other Non-Current Liabilities for Q3 2023 stood at $263000.0, down from $527000.0 in the prior quarter.
Over the last five years, Other Non-Current Liabilities for IBIO reached as high as $1.1 million in Q4 2022 and fell as low as $263000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	iBio	172.22 Mn	172.22 Mn	-

Download Data